Welcome to our dedicated page for TFF Pharmaceuticals news (Ticker: $TFFP), a resource for investors and traders seeking the latest updates and insights on TFF Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TFF Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TFF Pharmaceuticals's position in the market.
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (TFFP) announced that its CEO will present a corporate overview at the 36th Annual Roth Conference. The company focuses on innovative drug products using Thin Film Freezing technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
-
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (TFFP) will present data from the Phase 2 trial of Voriconazole Inhalation Powder for the treatment of invasive pulmonary aspergillosis at the AAAM Conference. The presentation will be made by Dr. Zamaneh Mikhak, the Chief Medical Officer of TFF Pharmaceuticals, on January 26th, 2024, in Milan, Italy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.88%
Tags
-
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced the acceptance of a late-breaking abstract for presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting, featuring initial data from the Company’s ongoing Phase 2 study of Tacrolimus Inhalation Powder (TFF TAC). The study aims to prevent lung transplant rejection, addressing the high unmet medical need in lung transplantation with a 5-year mortality rate of approximately 50%. Professor Gregory Snell, Medical Head of Lung Transplant Service at the Alfred Hospital, expressed optimism about the potential of TFF TAC in optimizing immunosuppression in the lung while avoiding toxicities associated with systemically administered immunosuppressive therapies. The presentation will take place in Prague, Czech Republic from April 10-13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced positive initial data from the Company’s ongoing Phase 2 trials of TFF VORI and TFF TAC, along with clinical data from the ongoing TFF VORI Expanded Access Program (EAP). The clinical data demonstrated the efficacy and favorable safety and tolerability of TFF VORI and TFF TAC in rare disease indications with high unmet medical need. The Company plans to accelerate the initiation of registration-enabling studies based on the promising Phase 2 data for both products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.63%
Tags
-
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) to host conference call and webcast to review initial data from ongoing Phase 2 trials of TFF VORI and TFF TAC on Tuesday, December 19th at 8:30 am ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.63%
Tags
-
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) will undergo a reverse stock split at a ratio of 1 post-split share for every 25 pre-split shares, effective December 19, 2023. This move aims to reduce the number of issued shares from 59,133,574 to approximately 2,365,343 shares, with proportional adjustments to equity awards and warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2045.32%
Tags
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) appoints Thomas B. King to its Board of Directors. King brings over 30 years of executive leadership and board experience in the life sciences industry, with a track record of successful stock offerings and M&A transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
-
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) appoints Michael Patane, Ph.D., a leader in drug discovery and development, to its Board of Directors, bringing two decades of experience to the clinical-stage biopharmaceutical company focused on innovative drug products based on its patented Thin Film Freezing (TFF) technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.43%
Tags
-
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) appoints Catherine Lee, J.D. to its Board of Directors. With over 25 years of legal and business experience, Ms. Lee brings a wealth of knowledge to the company, having served as General Counsel and Corporate Secretary for multiple companies within the life sciences sector. Her appointment is expected to contribute to TFF Pharmaceuticals' strategic decision-making, product development, and potential partnership opportunities, as the company advances its two clinical programs and its patented Thin Film Freezing (TFF) technology platform gains recognition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.43%
Tags
Rhea-AI Summary
TFF Pharmaceuticals, Inc. (TFFP) to participate in the 2023 Benchmark Discovery One-on-One Investor Conference in New York City. The company has two products in Phase 2 development and is expecting to release interim data from both studies in December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
TFF Pharmaceuticals, Inc.
Nasdaq:TFFP
TFFP Rankings
TFFP Stock Data
5.44M
2.23M
4.71%
13.87%
3.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
AUSTIN
About TFFP
tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.